FST 344
Also known as: Follistatin 344, FST-344, Myostatin Inhibitor
A follistatin isoform that inhibits myostatin for muscle growth and strength.
Overview
Follistatin 344 is a glycoprotein that inhibits myostatin and activin, two negative regulators of muscle growth. By blocking these proteins, FST-344 allows for increased muscle mass and strength. It has garnered significant interest in both medical and performance contexts.
Mechanism of Action
Binds to and neutralizes myostatin (GDF-8) and activin A, removing the brakes on muscle growth. This allows increased satellite cell proliferation and muscle protein synthesis. Also affects FSH through activin inhibition.
Pharmacokinetics
Gene therapy or protein delivery approaches studied. Direct protein injection has limited half-life. Gene therapy provides sustained expression.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Research
100-300 mcg
Daily to weekly
4-8 weeks
Research protocols vary widely
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Potent myostatin inhibitor
- 2Significant muscle gains in animal studies
- 3Gene therapy trials for muscle diseases
- 4Also affects reproductive hormones via activin
Side Effects & Contraindications
Reported Side Effects
- Potential FSH suppression
- Unknown long-term effects
Contraindications
- Reproductive concerns
- Hormone-sensitive conditions
Safety Considerations
Research compound. May affect reproductive function via activin inhibition. Gene therapy approaches carry typical risks. Limited human safety data.
Storage Requirements
Store at -20C
Scientific References
- 1